{"name":"Therapeutic Concepts","slug":"therapeutic-concepts","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Kaletra","genericName":"Kaletra","slug":"kaletra","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Kaletra","genericName":"Kaletra","slug":"kaletra","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNUGZUSUxJXzQ4cnlwZ2tUS09wYjZyNHJ6cVJucFdXODA1U1N1cE90QWhFTDB3emVxcS1KazlPb2RZMExCYUh3eExvU1hic0JuSlF6dnB0VUdMQTdTVVVOTXJPQTFoMTVjY20zSHZnME9Pblh5N2JJZ3M3TktzYXpDOVFWZWp3RTRPcFpKUEJMMFhlRFo2bTFj?oc=5","date":"2026-03-03","type":"trial","source":"PharmaTimes","summary":"Quell launches chill phase 1/2 trial for novel cartreg therapy - PharmaTimes","headline":"Quell launches chill phase 1/2 trial for novel cartreg therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQMUlaUHp6ZGQ4Ymh0ekFYbjJPTzgxcHcxVjBpOWFmM2tselpBbjExV1JYUklXMG9mR2dNdFVNRnNHV3VtUnRwaEdYd0xoNG1iaEFlT3ZHZEVxTjkyU01wcDBfRmtfS2U4bktzV3B3MktPZmJhTE5CcjJQNkZJd2Q5TnNlUkhZMkFlN29qN3VCRQ?oc=5","date":"2026-02-18","type":"trial","source":"Yahoo Finance","summary":"Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases - Yahoo Finance","headline":"Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSlE5WlVlNkZRQUtxUHJXOWQ1Z21NVHRkVGRzS25YdDkxV0xoOEZuRGJsbktXMGZ3bXJoRjBzYll2Y09sdkFPcTdSZ1FaUDh3OWNvNEZueU13U0NlNklKdDd1ZDQtbEZWdHJtM0xDd3pSZ2xOWEpQNk9CU3l3TFRrSHNpZnVBcFR5UlVKTjVMU3hNNVdjb2Nha2xDWnJhekRvZmJKT043UW5FaDA?oc=5","date":"2026-02-12","type":"pipeline","source":"Mercer University","summary":"Pharmacy professor awarded grant to advance therapy for drug-resistant hypertension - Mercer University","headline":"Pharmacy professor awarded grant to advance therapy for drug-resistant hypertension","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPWjF2aXcyck1wZGVDdGE1cXd2NnMxZU5talNFWUx4NC04YXpjSktTb3NHQnNHWGhjOUhMdzMxMTFiQnlVZFo3RWg3YVFGRWxuZHpyWHZJNG10T0Y2VXFGNGhDNGI0amlmaTFKV0RmRXdfeUlkYXV5NDNqeVZlTXRST3VxZVRaZHpFLWtTd05nR2ZFdlVqb0ptbGF4N2hnVXpYbUJZVw?oc=5","date":"2026-01-28","type":"pipeline","source":"PharmTech.com","summary":"Rare Disease Therapies: From Niche Experiment to Strategic Growth Engine - PharmTech.com","headline":"Rare Disease Therapies: From Niche Experiment to Strategic Growth Engine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNazh2WTVKU1lfWmVSNjRONVFmTUh1TDZycU5CSGU0Q3ZCSW4yM0VONjktemk2QlRhdFFPaUFFdW5zQjZXWmxNaFcySlFTc05DRFVQcjg2b1pyYk1EbG92cDZWTXNkalJENGZ1bnRGTl9jUDBJMFVXa2hrbllyTkoxQ05HUEswZUtXNk16TmhvNWJvdG1RWXVINQ?oc=5","date":"2026-01-09","type":"pipeline","source":"PwC","summary":"Future of Pharma: Breakthroughs at Scale - PwC","headline":"Future of Pharma: Breakthroughs at Scale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE13ZnR2bzdYbzIzN3FIVmp3cXYyTlpEM19wRHBCVE5rdy12Qk9xM3JJb2l6VWI2TnRTb0lJX2FFeTRQYkp0ZDFmWG1RMjV2ZENhRkRvRGI2NEZMc2VlcDhr?oc=5","date":"2026-01-08","type":"pipeline","source":"Nature","summary":"Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation - Nature","headline":"Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1TYWY1YTI0WXdaMXNfRWdZZy1qUHdrZjdVcTJhdklKb2Nmcm52UWlWZjJBWkF6X2VJZWhZSWhvXzNaWVQzb3lRTHg3TXBJcmR0MzdSX0dpTXgxa3hQaGdXTg?oc=5","date":"2025-12-05","type":"pipeline","source":"The Pharma Letter","summary":"Evinco Therapeutics - The Pharma Letter","headline":"Evinco Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQRThoSE5oRWpsQzdDVEZrZEhHR0d0TnZwYXZNM3NhYkVzLVR4SWlYcXprQUVxd1EyTDdWSVljY2h1SGgyN0F4czFQbFBabk0wSUFDeWNPR2N6d2pUM3ZiVzJxbU11VXZpbENKbXZZVWtSV3o3clZZemFTb0JzTFljM2lkMDcyRXc?oc=5","date":"2025-12-01","type":"pipeline","source":"BioSpace","summary":"6 Companies Hanging On in Cell Therapy - BioSpace","headline":"6 Companies Hanging On in Cell Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPcUdNWDA2bVhCdzY3THRzV2Q3NjNNMkNWbXpsbk42RThsLU9RWTFqb3dnbzA2SFBpTGJEN2plLXN0MDBpQWFSQTNLUzRyWUhSOGlDTWhqOF9DV2ZzN1FVSmUxRmExSVBkd3RsLUxzczFIeUkwcFJoeDhGa19hcmxKb2R5TWR5ZTE3bWt5WV9RSDhUalRaQ0s4N3V0SDJlaFdJanc?oc=5","date":"2025-10-17","type":"pipeline","source":"BioSpace","summary":"Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back - BioSpace","headline":"Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOWXpxaHlmUG0zQ2NwaXRQdUVxZkh3cndRalN3SWpEaVRYUUVNZ2Q3SnlEX2Jrd2dKSjdZNDNJM1BlTFhZUkVLaVpSZl8zLUVBXzdpUjMwWmM2Y2MzZnd6Qi1EZE5UTWVzNElyYnNGUll6Tmlib2U2WjVzcFlYZGhTbmNxV1gycEhMMVBtQXpHWkZkMWNGR2NnVHZSQktPbzVxOEZJaEotUk94cTJBcGhxTVJncGVRcTVTMTJtcUo2U0c?oc=5","date":"2025-07-02","type":"pipeline","source":"Business Weekly","summary":"Less than 0.02 per cent of therapeutic concepts hit the market, symposium guests learn - Business Weekly","headline":"Less than 0.02 per cent of therapeutic concepts hit the market, symposium guests learn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQR1EyLVlLamdtZ3IyMDRGZUlOTnhzcFAyUlJwVDhPeVVJZlN2RGNaV2JYYjhSQ01KWk5vV1dIVmN4S3FRMHFIQXdPZVl2cUpVNjZ3Y3BuS1VaTTJWSHNOVmJRTW5fVU1KbTBRNW42OC1tRXlSS0ZMZFpNS2FxcVltNjhFYm9qVW9tUi1GNUJvcGw3QQ?oc=5","date":"2025-04-04","type":"pipeline","source":"the-scientist.com","summary":"Tapping Into the Full Therapeutic Potential of GLP-1 - the-scientist.com","headline":"Tapping Into the Full Therapeutic Potential of GLP-1 - the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNTlhUbVhZNUE3NXFsQTE3anA3ZGJJNENLVHhZTy0xUUxxNVdVM2t3Z2M5Y0JhVFpXVGxrbzlWX1BZa1dCWUM1N0FsTUx4VXJVc2NqbUNaXzlxQ0pNemllZVFUeFdEb244X081cUsyZGJKYjdreFo4b25ZbjhvSF8wd3FUOWlENG5aSVJFNA?oc=5","date":"2024-06-26","type":"pipeline","source":"Frontiers","summary":"Sepsis—Pathophysiology and Therapeutic Concepts - Frontiers","headline":"Sepsis—Pathophysiology and Therapeutic Concepts","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}